Evogene Ltd.
TASE:EVGN Rapport sur les actions
Capitalisation boursière : ₪36.7m
Evogene Bilan de santé
Santé financière contrôle des critères 6/6 Evogene possède un total de capitaux propres de $19.9M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $41.0M et de $21.0M.
Informations clés Ratio de couverture des intérêts n/a Argent liquide US$20.91m Fonds propres US$19.94m Total du passif US$21.03m Total des actifs US$40.97m
Mises à jour récentes de la santé financière
Afficher toutes les mises à jour
Evogene Ltd. to Report Q3, 2024 Results on Nov 21, 2024 Nov 07
Evogene Ltd. Announces Executive Changes Sep 17
Evogene Ltd. to Report Q2, 2024 Results on Aug 22, 2024 Aug 12
Evogene Ltd. to Report Q1, 2024 Results on May 23, 2024 May 11
Evogene Ltd., Annual General Meeting, Jun 06, 2024 May 01 Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million. Mar 30
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification Mar 21
Full year 2023 earnings released: US$0.52 loss per share (vs US$0.65 loss in FY 2022) Mar 07
We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate Mar 05
Evogene Ltd. to Report Q4, 2023 Results on Mar 07, 2024 Feb 27
Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024 Dec 19
New major risk - Share price stability Dec 06
New minor risk - Shareholder dilution Nov 20
Third quarter 2023 earnings released: US$0.081 loss per share (vs US$0.16 loss in 3Q 2022) Nov 18
Evogene Ltd. to Report Q3, 2023 Results on Nov 15, 2023 Nov 03
Will Evogene (TLV:EVGN) Spend Its Cash Wisely? Oct 09
Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2022) Aug 18
Evogene Ltd. to Report Q2, 2023 Results on Aug 17, 2023 Aug 01
Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery Jul 26
Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program Jul 22
Will Evogene (TLV:EVGN) Spend Its Cash Wisely? Jun 26
New minor risk - Share price stability Jun 21
Evogene Ltd., Annual General Meeting, May 11, 2023 May 06
Evogene Ltd. to Report Q1, 2023 Results on May 18, 2023 May 05
We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate Mar 13
Full year 2022 earnings released: US$0.65 loss per share (vs US$0.69 loss in FY 2021) Mar 11
Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.19 loss in 3Q 2021) Nov 21
Evogene Ltd. to Report Q3, 2022 Results on Nov 17, 2022 Nov 08
Here's Why We're Watching Evogene's (TLV:EVGN) Cash Burn Situation Oct 07
Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.15 loss in 2Q 2021) Sep 02
Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule Aug 27
Evogene Ltd., Annual General Meeting, Sep 08, 2022 Aug 04
Evogene Ltd. to Report Q2, 2022 Results on Aug 31, 2022 Aug 03
We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate Jun 16
Eyal Ronen Joins as Executive Vice President of Business Development of Evogene Ltd., Effective as of June 12, 2022 Jun 02
First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.17 loss in 1Q 2021) May 28
Evogene Ltd. to Report Q1, 2022 Results on May 26, 2022 May 12
High number of new directors Mar 29
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 11
Will Evogene (TLV:EVGN) Spend Its Cash Wisely? Mar 02
Evogene Ltd. to Report Q4, 2021 Results on Mar 10, 2022 Feb 16
High number of new directors Feb 04
Evogene Ltd. Announces Executive Changes Feb 03
Chief Executive Officer of AgPlenus Ltd. Douglas Eisner has left the company Dec 01
Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2020) Nov 18
High number of new and inexperienced directors Nov 02
Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.17 loss in 2Q 2020) Aug 12
First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 1Q 2020) May 28
Here's Why We're Not Too Worried About Evogene's (TLV:EVGN) Cash Burn Situation May 28
Full year 2020 earnings released: US$0.83 loss per share (vs US$0.70 loss in FY 2019) Apr 04
Evogene Ltd. to Report Q4, 2020 Results on Mar 03, 2021 Feb 18
New 90-day high: ₪25.00 Feb 04
Companies Like Evogene (TLV:EVGN) Are In A Position To Invest In Growth Jan 21
New 90-day high: ₪19.10 Jan 14
New 90-day high: ₪14.94 Dec 24
What Can We Make Of Evogene's (TLV:EVGN) CEO Compensation? Nov 30
Third quarter 2020 earnings released: US$0.18 loss per share Nov 19
Evogene Ltd. to Report Q3, 2020 Results on Nov 18, 2020 Nov 03
First half earnings released Sep 17
New 90-day high - ₪9.46 Sep 16
New 90-day high - ₪5.63 Aug 27
New 90-day high - ₪4.17 Aug 10
First half earnings released Aug 06
Evogene Ltd. to Report Q2, 2020 Results on Aug 05, 2020 Jul 17
Analyse de la situation financière
Passif à court terme: Les actifs à court terme de EVGN ( $25.8M ) dépassent ses passifs à court terme ( $16.3M ).
Passif à long terme: Les actifs à court terme de EVGN ( $25.8M ) dépassent ses passifs à long terme ( $4.7M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: EVGN est sans dette.
Réduire la dette: EVGN n'a eu aucune dette au cours des 5 dernières années.
Analyse des pistes de trésorerie Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: EVGN dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.
Prévisions de trésorerie: EVGN devrait disposer d'une marge de trésorerie suffisante pour 11 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.
Découvrir des entreprises saines Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
